CY1109347T1 - Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης - Google Patents

Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης

Info

Publication number
CY1109347T1
CY1109347T1 CY20091100900T CY091100900T CY1109347T1 CY 1109347 T1 CY1109347 T1 CY 1109347T1 CY 20091100900 T CY20091100900 T CY 20091100900T CY 091100900 T CY091100900 T CY 091100900T CY 1109347 T1 CY1109347 T1 CY 1109347T1
Authority
CY
Cyprus
Prior art keywords
signal transducer
combination consisting
combination
derivative
inhibitor
Prior art date
Application number
CY20091100900T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Carl-Henrik Heldin
Arne Östman
Kristian Pietras
Terence O´Reilly
John David Rothermel
Peter Traxler
Markus Wartmann
Ralf Brandt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109347T1 publication Critical patent/CY1109347T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αφορά έναν συνδυασμό που αποτελείται από (α) έναν αναστολέα μεταλλαγής σήματος που επιλέγεται από έναν αναστολέα κινάσης τυροσίνης υποδοχέα PDGF (παράγοντας ανάπτυξης που προέρχεται από τα αιμοπετάλια) και ένα ενεργό συστατικό στοιχείο που μειώνει τη δραστηριότητα του επιδερμικού αυξητικού παράγοντα (EGF) ένα παράγωγο εποθιλόνης του τύπου (I) στην οποία ένωση το Α δηλώνει το Ο ή το NRn όπου το Rn είναι υδρογόνο ή κάτω αλκύλιο, το R είναι υδρογόνο ή κάτω αλκύλιο, και το Ζ είναι Ο ή ένας δεσμός και προαιρετικά τουλάχιστον έναν φαρμακευτικά αποδεκτό φορέα για ταυτόχρονη, ξεχωριστή ή συνεπαγόμενη χρήση, πιο συγκεκριμένα, για την καθυστέρηση της εξέλιξης μιας πολλαπλασιαστικής ασθένειας ή για τη θεραπεία αυτής, μια φαρμακευτική ένωση που περιλαμβάνει τον εν λόγω συνδυασμό, η χρήση του εν λόγω συνδυασμού για την παρασκευή ενός φαρμάκου για την καθυστέρηση της εξέλιξης ή για τη θεραπεία μιας πολλαπλασιαστικής ασθένειας, ένα εμπορικό πακέτο ή προϊόν που αποτελείται από τον εν λόγω συνδυασμό ως συνδυασμένο παρασκεύασμα για ταυτόχρονη, ξεχωριστή ή συνεπαγόμενη χρήση, και τον εν λόγω συνδυασμό για χρήση σε μια μέθοδο θεραπείας ενός θερμόαιμου θηλαστικού, ιδιαίτερα του ανθρώπου.
CY20091100900T 2001-02-27 2009-08-28 Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης CY1109347T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P 2001-10-30 2001-10-30
EP02744903A EP1385522B1 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (1)

Publication Number Publication Date
CY1109347T1 true CY1109347T1 (el) 2014-07-02

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100900T CY1109347T1 (el) 2001-02-27 2009-08-28 Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης

Country Status (23)

Country Link
US (1) US7723339B2 (el)
EP (1) EP1385522B1 (el)
JP (1) JP4499359B2 (el)
KR (1) KR100848197B1 (el)
CN (1) CN1511036B (el)
AT (1) ATE434438T1 (el)
AU (1) AU2002308218B2 (el)
BR (1) BR0207649A (el)
CA (1) CA2439268C (el)
CY (1) CY1109347T1 (el)
DE (1) DE60232719D1 (el)
DK (1) DK1385522T3 (el)
ES (1) ES2326264T3 (el)
HK (1) HK1062266A1 (el)
IL (2) IL157466A0 (el)
MX (1) MXPA03007729A (el)
NO (1) NO325416B1 (el)
NZ (1) NZ527764A (el)
PL (1) PL207197B1 (el)
PT (1) PT1385522E (el)
RU (1) RU2313345C2 (el)
SK (1) SK287489B6 (el)
WO (1) WO2002067941A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
SK11082003A3 (sk) 2001-03-14 2004-08-03 Bristol-Myers Squibb Company Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
JP4477303B2 (ja) * 2001-05-16 2010-06-09 ノバルティス アーゲー N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
AU2002349013A1 (en) * 2001-10-29 2003-05-12 Novartis Ag Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (el) * 1992-04-03 1994-06-21 Ciba Geigy Ag
HUP9900330A3 (en) * 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
EP1367057B1 (de) 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone E und F
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
EE200100422A (et) * 1999-02-11 2002-12-16 Schering Aktiengesellschaft Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
SK287489B6 (sk) 2010-11-08
RU2003127392A (ru) 2005-03-27
MXPA03007729A (es) 2003-12-04
PL207197B1 (pl) 2010-11-30
WO2002067941A8 (en) 2003-12-18
WO2002067941A2 (en) 2002-09-06
PL363288A1 (en) 2004-11-15
NO325416B1 (no) 2008-04-21
DE60232719D1 (de) 2009-08-06
JP2004527493A (ja) 2004-09-09
ATE434438T1 (de) 2009-07-15
IL157466A (en) 2012-04-30
PT1385522E (pt) 2009-09-04
RU2313345C2 (ru) 2007-12-27
US7723339B2 (en) 2010-05-25
BR0207649A (pt) 2004-03-09
WO2002067941A3 (en) 2003-11-20
CA2439268A1 (en) 2002-09-06
SK10712003A3 (sk) 2004-02-03
US20040132754A1 (en) 2004-07-08
IL157466A0 (en) 2004-03-28
EP1385522A2 (en) 2004-02-04
AU2002308218B2 (en) 2005-11-10
KR20040025900A (ko) 2004-03-26
CA2439268C (en) 2010-01-19
CN1511036A (zh) 2004-07-07
NO20033769D0 (no) 2003-08-25
HK1062266A1 (en) 2004-10-29
NZ527764A (en) 2006-01-27
ES2326264T3 (es) 2009-10-06
NO20033769L (no) 2003-08-25
EP1385522B1 (en) 2009-06-24
KR100848197B1 (ko) 2008-07-24
DK1385522T3 (da) 2009-10-12
JP4499359B2 (ja) 2010-07-07
CN1511036B (zh) 2010-05-05

Similar Documents

Publication Publication Date Title
CY1109347T1 (el) Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης
PL371466A1 (en) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
NO20076323L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat
IL176070A0 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
BR0314112A (pt) Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
CY2008010I2 (el) Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
DE10196382T1 (de) Halbleiterchip und Halbleitervorrichtung, für die der Halbleiterchip verwendet wird
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
NO20031833D0 (no) Behandling av gastrointestinale stromatumorer
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
EE200300041A (et) Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid
DE60308337D1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
ATE289306T1 (de) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen
DE10204822B8 (de) Eingabe-/Ausgabeleitungs-Abtastverstärker eines Halbleiterspeicherbauelementes
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
NO20023956D0 (no) Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser
DE60204791D1 (de) Synthese von 4-(piperidyl) (2-pyridyl)methanon-(e)-o-methyloxim und seinen salzen
EE200000638A (et) 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm
ATE348615T1 (de) 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
DK1353906T3 (da) Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf
SI1436282T1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts